相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer
Tawee Tanvetyanon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Ganoderma lucidum polysaccharides can induce human monocytic leukemia cells into dendritic cells with immuno-stimulatory function
Wing Keung Chan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2008)
Medicinal importance of fungal β-(1→3), (1→6)-glucans
Jiezhony Chen et al.
MYCOLOGICAL RESEARCH (2007)
Liquid chromatography/mass spectrometry analysis of PHY906, a Chinese medicine formulation for cancer therapy
Min Ye et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2007)
An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma
H. Miles Prince et al.
LEUKEMIA & LYMPHOMA (2007)
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study
James R. Berenson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Arsenic trioxide in patients with myelodysplastic syndromes: A phase II multicenter study
N Vey et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The use of thalidomide in myeloma therapy as an effective anticancer drug
Daniel M. -Y. Sze et al.
CURRENT CANCER DRUG TARGETS (2006)
Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients - A phase 2 trial
RM Abou-Jawde et al.
MEDICAL ONCOLOGY (2006)
Ganoderma lucidum mycelium and spore extracts as natural adjuvants for immunotherapy
WK Chan et al.
JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE (2005)
Arsenic trioxide uptake by human and rat aquaglyceroporins
ZJ Liu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients
P Rousselot et al.
LEUKEMIA (2004)
Either interleukin-12 or interferon-γ can correct the dendritic cell defect induced by transforming growth factor β1 in patients with myeloma
R Brown et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Arsenic trioxide-induced apoptosis in myeloma cells:: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL
Q Liu et al.
BLOOD (2003)
Dectin-1 mediates the biological effects of β-glucans
GD Brown et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Bioactive polysaccharides from traditional Chinese medicine herbs as anticancer adjuvants
R Chang
JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE (2002)
Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10
RD Brown et al.
BLOOD (2001)
Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+CD57+CD28- compartment
DMY Sze et al.
BLOOD (2001)
Clinical pharmacology of thalidomide
T Eriksson et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
FE Davies et al.
BLOOD (2001)
Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As2O3) on myeloma cells
S Deaglio et al.
LEUKEMIA RESEARCH (2001)
分享论文
